BRIEF published on 12/11/2025 at 23:05, 3 months 13 days ago Xenetic Biosciences ajourne son assemblée générale annuelle des actionnaires de 2025. Instructions De Vote Quorum Biosciences Xénétiques Assemblée Générale Des Actionnaires Ajournement De 2025
BRIEF published on 12/11/2025 at 23:05, 3 months 13 days ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 3 months 13 days ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 4 months 5 days ago Xenetic Biosciences étend sa collaboration avec Scripps Research Biopharmaceutique Traitement Du Cancer DNase I Thérapie CAR-T Recherche Scripps
BRIEF published on 11/19/2025 at 14:50, 4 months 5 days ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 4 months 5 days ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 4 months 11 days ago Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2025 Résultats Financiers Essais Cliniques Augmentation Des Revenus Technologie DNase Carcinome Pancréatique
BRIEF published on 11/13/2025 at 14:50, 4 months 11 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 4 months 11 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 5 months 14 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
Published on 03/24/2026 at 23:00, 3 hours 40 minutes ago Redwood AI Selected to Present at BIO-Europe Spring 2026, Europe's Largest Springtime Biotech Partnering Event
Published on 03/24/2026 at 18:55, 7 hours 45 minutes ago Norse Gold Announces Closing of Private Placement Financing and Pending Reactivation on the TSX-V
Published on 03/24/2026 at 13:30, 13 hours 10 minutes ago GGL Resources Corp. Announces Closing of Earn-In Agreement with Nelson Resources Limited on Its Gold Point High-Grade Gold-Silver Project, Nevada
Published on 03/24/2026 at 13:30, 13 hours 10 minutes ago Innodata Announces Date of Annual Shareholder Meeting
Published on 03/24/2026 at 21:08, 5 hours 32 minutes ago Linedata Services: Linedata annonce le transfert de son contrat de liquidité auprès de Portzamparc (Groupe BNP Paribas)
Published on 03/24/2026 at 19:49, 6 hours 51 minutes ago EEII AG: Cancellation of the Extraordinary General Meeting of March 26, 2026
Published on 03/24/2026 at 19:41, 6 hours 58 minutes ago ASMALLWORLD Honoured with Regional Virtuoso Award in Continental Europe for “Most Engaged Member” in Recognition of Their Exceptional Contribution
Published on 03/24/2026 at 19:05, 7 hours 35 minutes ago WBS Power Advances 3.2 GW Energy Infrastructure for Hyperscale Data Center Campus
Published on 03/24/2026 at 18:39, 8 hours ago EQS-Adhoc: FORTEC Elektronik Aktiengesellschaft: Adjustment of the earnings forecast for the financial year 2025/2026
Published on 03/24/2026 at 17:46, 8 hours 54 minutes ago NRJ GROUP - Press release annual results 2025
